Base de dados : MEDLINE
Pesquisa : D03.633.100.810.410 [Categoria DeCS]
Referências encontradas : 2003 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 201 ir para página                         

  1 / 2003 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28502942
[Au] Autor:Ikeda J; Matsushima A; Ishii W; Goto T; Takahashi K; Nakamichi K; Saijo M; Sekijima Y; Ikeda SI
[Ad] Endereço:Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Japan.
[Ti] Título:Brain Biopsy Is More Reliable than the DNA test for JC Virus in Cerebrospinal Fluid for the Diagnosis of Progressive Multifocal Leukoencephalopathy.
[So] Source:Intern Med;56(10):1231-1234, 2017.
[Is] ISSN:1349-7235
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:The current standard diagnostic approach for progressive multifocal leukoencephalopathy (PML) is to perform a DNA test to identify the presence of the JC virus in cerebrospinal fluid (CSF). A 32-year-old woman with a 5-year history of systemic lupus erythematosus developed right hemiplegia and motor aphasia. MRI revealed a large white matter lesion in the left frontal lobe. JC virus DNA was undetectable in the CSF, but a brain biopsy showed typical histopathology and a high DNA load of the JC virus. The patient was treated with mefloquine and mirtazapine, and is currently alive at 24 months after onset. An early brain biopsy may therefore be important for making a timely diagnosis of PML.
[Mh] Termos MeSH primário: Biópsia
Encéfalo/diagnóstico por imagem
Encéfalo/fisiopatologia
DNA Viral/líquido cefalorraquidiano
Vírus JC/genética
Leucoencefalopatia Multifocal Progressiva/diagnóstico
Leucoencefalopatia Multifocal Progressiva/tratamento farmacológico
[Mh] Termos MeSH secundário: Antagonistas Adrenérgicos alfa/uso terapêutico
Adulto
Antimaláricos/uso terapêutico
Feminino
Seres Humanos
Imagem por Ressonância Magnética
Mefloquina/uso terapêutico
Mianserina/análogos & derivados
Mianserina/uso terapêutico
Reprodutibilidade dos Testes
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic alpha-Antagonists); 0 (Antimalarials); 0 (DNA, Viral); 250PJI13LM (Mianserin); A051Q2099Q (mirtazapine); TML814419R (Mefloquine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170516
[St] Status:MEDLINE
[do] DOI:10.2169/internalmedicine.56.7689


  2 / 2003 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28500806
[Au] Autor:McLean ARD; Boel M; McGready R; Ataide R; Drew D; Tsuboi T; Beeson JG; Nosten F; Simpson JA; Fowkes FJI
[Ad] Endereço:Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia.
[Ti] Título:Antibody Responses to and and Prospective Risk of spp. Infection Postpartum.
[So] Source:Am J Trop Med Hyg;96(5):1197-1204, 2017 May.
[Is] ISSN:1476-1645
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:AbstractPostpartum women may have an altered susceptibility to and . The relationship between naturally acquired malarial immunity and susceptibility to malaria postpartum is yet to be determined. IgG levels were measured against and antigens from delivery in 201 postpartum and 201 nonpregnant controls over 12 weeks. Associations between time-varying antibody levels and time to first microscopically confirmed species-specific infection were determined by Cox regression. Associations between antibody levels and prospective risk of infection were similar in postpartum and control women. A 2-fold increase in antibody levels was associated with increased prospective risk of infection (hazard ratio [HR] range = 1.37-1.94). Antibody levels against most antigens displayed no association with prospective risk of infection (HR range = 1.02-1.05) with the exception of MSP1 antibodies that were weakly associated with prospective risk of infection (HR = 1.14 (95% confidence interval = 1.02, 1.28) per 2-fold increase in levels). Associations between antibody levels and prospective risk of infection attenuated when adjusted for documented retrospective exposure. Serology may be a useful tool to predict and monitor women at increased risk of infection postpartum, particularly in the absence of a detailed history of retrospective infections.
[Mh] Termos MeSH primário: Imunidade Adaptativa
Anticorpos Antiprotozoários/sangue
Imunoglobulina G/sangue
Malária Falciparum/diagnóstico
Malária Vivax/diagnóstico
Parasitemia/diagnóstico
[Mh] Termos MeSH secundário: Antimaláricos/uso terapêutico
Artemisininas/uso terapêutico
Cloroquina/uso terapêutico
Estudos de Coortes
Resistência à Doença
Suscetibilidade a Doenças
Feminino
Seres Humanos
Malária Falciparum/tratamento farmacológico
Malária Falciparum/imunologia
Malária Falciparum/parasitologia
Malária Vivax/tratamento farmacológico
Malária Vivax/imunologia
Malária Vivax/parasitologia
Mefloquina/uso terapêutico
Proteína 1 de Superfície de Merozoito/sangue
Proteína 1 de Superfície de Merozoito/imunologia
Parasitemia/tratamento farmacológico
Parasitemia/imunologia
Parto
Plasmodium falciparum/crescimento & desenvolvimento
Plasmodium falciparum/patogenicidade
Plasmodium vivax/crescimento & desenvolvimento
Plasmodium vivax/patogenicidade
Gravidez
Modelos de Riscos Proporcionais
Risco
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Protozoan); 0 (Antimalarials); 0 (Artemisinins); 0 (Immunoglobulin G); 0 (Merozoite Surface Protein 1); 60W3249T9M (artesunate); 886U3H6UFF (Chloroquine); TML814419R (Mefloquine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170803
[Lr] Data última revisão:
170803
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170514
[St] Status:MEDLINE
[do] DOI:10.4269/ajtmh.16-0690


  3 / 2003 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28487213
[Au] Autor:Tan KR; Henderson SJ; Williamson J; Ferguson RW; Wilkinson TM; Jung P; Arguin PM
[Ad] Endereço:Malaria Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: ktan@cdc.gov.
[Ti] Título:Long term health outcomes among Returned Peace Corps Volunteers after malaria prophylaxis, 1995-2014.
[So] Source:Travel Med Infect Dis;17:50-55, 2017 May - Jun.
[Is] ISSN:1873-0442
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: A primary reason for non-adherence to malaria chemoprophylaxis is fear of latent side effects. We examined latent effects of malaria chemoprophylaxis among Returned Peace Corps Volunteers (RPCVs). METHODS: During July 18-September 16, 2016, RPCVs who served during 1995-2014 with an e-mail address in Peace Corps' RPCV database were invited to take an internet-based survey on malaria prophylaxis and medical diagnoses. "Good adherence" meant taking prophylaxis "as prescribed" or "most of the time." Prevalence of diseases diagnosed after Peace Corps service was compared between users and nonusers of each antimalarial using log-binomial regression. RESULTS: Of 8931 participants (11% response rate), 5055 (57%) took chemoprophylaxis. Initial chemoprophylaxis was mefloquine 59%, chloroquine 13%, doxycycline 16%, atovaquone-proguanil 4%, and "other" 8%. Sixty percent reported good adherence. Mefloquine users had the best adherence (67% good adherence). Prevalences of most diseases were similar between exposed and unexposed groups. Certain psychiatric diagnoses were slightly more likely among mefloquine users (PR 1.14, 95% CI [1.04-1.25], P = 0.0048). When excluding those with prior psychiatric illness, there were no differences in psychiatric diagnosis rates. CONCLUSION: Malaria chemoprophylaxis use by Peace Corps Volunteers is safe. Avoiding mefloquine use in those with prior psychiatric illness can reduce psychiatric side effects.
[Mh] Termos MeSH primário: Antimaláricos/uso terapêutico
Quimioprevenção/estatística & dados numéricos
Malária/prevenção & controle
Adesão à Medicação/estatística & dados numéricos
Peace Corps
[Mh] Termos MeSH secundário: Adulto
Atovaquona/uso terapêutico
Cloroquina/uso terapêutico
Estudos Transversais
Doxiciclina/uso terapêutico
Combinação de Medicamentos
Feminino
Seres Humanos
Masculino
Mefloquina/uso terapêutico
Proguanil/uso terapêutico
Viagem
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antimalarials); 0 (Drug Combinations); 0 (atovaquone, proguanil drug combination); 886U3H6UFF (Chloroquine); N12000U13O (Doxycycline); S61K3P7B2V (Proguanil); TML814419R (Mefloquine); Y883P1Z2LT (Atovaquone)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171024
[Lr] Data última revisão:
171024
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170511
[St] Status:MEDLINE


  4 / 2003 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28363636
[Au] Autor:McCarthy JS; Lotharius J; Rückle T; Chalon S; Phillips MA; Elliott S; Sekuloski S; Griffin P; Ng CL; Fidock DA; Marquart L; Williams NS; Gobeau N; Bebrevska L; Rosario M; Marsh K; Möhrle JJ
[Ad] Endereço:QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia; Q-Pharm Pty Ltd, Herston, QLD, Australia. Electronic address: james.mccarthy@qimrberghofer.edu.au.
[Ti] Título:Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study.
[So] Source:Lancet Infect Dis;17(6):626-635, 2017 Jun.
[Is] ISSN:1474-4457
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: DSM265 is a novel antimalarial that inhibits plasmodial dihydroorotate dehydrogenase, an enzyme essential for pyrimidine biosynthesis. We investigated the safety, tolerability, and pharmacokinetics of DSM265, and tested its antimalarial activity. METHODS: Healthy participants aged 18-55 years were enrolled in a two-part study: part 1, a single ascending dose (25-1200 mg), double-blind, randomised, placebo-controlled study, and part 2, an open-label, randomised, active-comparator controlled study, in which participants were inoculated with Plasmodium falciparum induced blood-stage malaria (IBSM) and treated with DSM265 (150 mg) or mefloquine (10 mg/kg). Primary endpoints were DSM265 safety, tolerability, and pharmacokinetics. Randomisation lists were created using a validated, automated system. Both parts were registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12613000522718 (part 1) and number ACTRN12613000527763 (part 2). FINDINGS: In part 1, 73 participants were enrolled between April 12, 2013, and July 14, 2015 (DSM265, n=55; placebo, n=18). In part 2, nine participants were enrolled between Sept 30 and Nov 25, 2013 (150 mg DSM265, n=7; 10 mg/kg mefloquine, n=2). In part 1, 117 adverse events were reported; no drug-related serious or severe events were reported. The most common drug-related adverse event was headache. The mean DSM265 peak plasma concentration (C ) ranged between 1310 ng/mL and 34 800 ng/mL and was reached in a median time (t ) between 1·5 h and 4 h, with a mean elimination half-life between 86 h and 118 h. In part 2, the log parasite reduction ratio at 48 h in the DSM265 (150 mg) group was 1·55 (95% CI 1·42-1·67) and in the mefloquine (10 mg/kg) group was 2·34 (2·17-2·52), corresponding to a parasite clearance half-life of 9·4 h (8·7-10·2) and 6·2 h (5·7-6·7), respectively. The median minimum inhibitory concentration of DSM265 in blood was estimated as 1040 ng/mL (range 552-1500), resulting in a predicted single efficacious dose of 340 mg. Parasite clearance was significantly faster in participants who received mefloquine than in participants who received DSM265 (p<0·0001). INTERPRETATION: The good safety profile, long elimination half-life, and antimalarial effect of DSM265 supports its development as a partner drug in a single-dose antimalarial combination treatment. FUNDING: Wellcome Trust, UK Department for International Development, Global Health Innovative Technology Fund, Bill & Melinda Gates Foundation.
[Mh] Termos MeSH primário: Antimaláricos/administração & dosagem
Mefloquina/uso terapêutico
Pirimidinas/administração & dosagem
Pirimidinas/farmacocinética
Triazóis/administração & dosagem
Triazóis/farmacocinética
[Mh] Termos MeSH secundário: Adolescente
Adulto
Antimaláricos/farmacocinética
Antimaláricos/uso terapêutico
Austrália
Método Duplo-Cego
Inibidores Enzimáticos/química
Inibidores Enzimáticos/farmacocinética
Meia-Vida
Seres Humanos
Malária Falciparum/tratamento farmacológico
Meia-Idade
Nova Zelândia
Oxirredutases atuantes sobre Doadores de Grupo CH-CH
Plasmodium falciparum
Pirimidinas/uso terapêutico
Triazóis/uso terapêutico
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE I; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antimalarials); 0 (DSM265); 0 (Enzyme Inhibitors); 0 (Pyrimidines); 0 (Triazoles); EC 1.3.- (Oxidoreductases Acting on CH-CH Group Donors); EC 1.3.5.2 (dihydroorotate dehydrogenase); TML814419R (Mefloquine)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170627
[Lr] Data última revisão:
170627
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170402
[St] Status:MEDLINE


  5 / 2003 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28192434
[Au] Autor:Lee SJ; Ter Kuile FO; Price RN; Luxemburger C; Nosten F
[Ad] Endereço:Mahidol Oxford Research Unit, Mahidol University, Bangkok, Thailand.
[Ti] Título:Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: A pooled analysis of 19, 850 individual patients.
[So] Source:PLoS One;12(2):e0168780, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Mefloquine (MQ) has been used for the treatment of malaria since the mid-1980s, first as monotherapy or as fixed combination with sulfadoxine-pyrimethamine (MSP) and since the mid-1990s in combination with artesunate. There is a renewed interested in MQ as part of a triple therapy for the treatment of multi-drug resistance P. falciparum malaria. The widespread use of MQ beyond south-East Asia has been constrained by reports of poor tolerability. Here we present the side effect profile of MQ for the treatment of uncomplicated malaria on the Thai-Myanmar/Cambodia borders. In total 19,850 patients received seven different regimens containing either 15 or 24-25 mg/kg of MQ, the latter given either as a single dose, or split over two or three days. The analysis focused on (predominantly) gastrointestinal and neuropsychiatric events as compared to the new fixed dose combination of MQ plus artesunate given as equal doses of 8 mg/kg MQ per day over three days. Gastrointestinal side effects were dose-dependent and associated with the severity of malaria symptoms. Serious neuropsychiatric side effects associated with MQ use were rare: for a single 25 mg/kg dose it was 11.9 per 10,000 treatments (95% confidence interval, CI, 4-285) vs. 7.8 (3-15) for the 15 mg/kg dose. The risk with 25 mg/kg was much higher when it was given as repeat dosing in patients who had failed treatment with 15 mg/kg MQ in the preceding month; (RR 6.57 (95% CI 1.33 to 32.4), p = 0.0077). MQ was best tolerated as 15 mg/kg or as 24 mg/kg when given over three days in combination with artesunate. We conclude that the tolerance of a single dose of MQ in the treatment of uncomplicated malaria is moderate, but can be improved by administering it as a split dose over three days.
[Mh] Termos MeSH primário: Malária/tratamento farmacológico
Mefloquina/uso terapêutico
Plasmodium falciparum/efeitos dos fármacos
Plasmodium vivax/efeitos dos fármacos
[Mh] Termos MeSH secundário: Adolescente
Adulto
Anorexia/induzido quimicamente
Antimaláricos/efeitos adversos
Antimaláricos/uso terapêutico
Artemisininas/efeitos adversos
Artemisininas/uso terapêutico
Criança
Pré-Escolar
Tontura/induzido quimicamente
Relação Dose-Resposta a Droga
Combinação de Medicamentos
Quimioterapia Combinada
Feminino
Interações Hospedeiro-Parasita/efeitos dos fármacos
Seres Humanos
Malária/parasitologia
Masculino
Mefloquina/efeitos adversos
Náusea/induzido quimicamente
Avaliação de Resultados (Cuidados de Saúde)/métodos
Avaliação de Resultados (Cuidados de Saúde)/estatística & dados numéricos
Plasmodium falciparum/fisiologia
Plasmodium vivax/fisiologia
Transtornos Psicóticos/etiologia
Pirimetamina/efeitos adversos
Pirimetamina/uso terapêutico
Sulfadoxina/efeitos adversos
Sulfadoxina/uso terapêutico
Tailândia
Vômito/induzido quimicamente
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antimalarials); 0 (Artemisinins); 0 (Drug Combinations); 37338-39-9 (fanasil, pyrimethamine drug combination); 60W3249T9M (artesunate); 88463U4SM5 (Sulfadoxine); TML814419R (Mefloquine); Z3614QOX8W (Pyrimethamine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170824
[Lr] Data última revisão:
170824
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170214
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0168780


  6 / 2003 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28134928
[Au] Autor:Burma NE; Bonin RP; Leduc-Pessah H; Baimel C; Cairncross ZF; Mousseau M; Shankara JV; Stemkowski PL; Baimoukhametova D; Bains JS; Antle MC; Zamponi GW; Cahill CM; Borgland SL; De Koninck Y; Trang T
[Ad] Endereço:Department of Comparative Biology and Experimental Medicine, University of Calgary, Calgary, Alberta, Canada.
[Ti] Título:Blocking microglial pannexin-1 channels alleviates morphine withdrawal in rodents.
[So] Source:Nat Med;23(3):355-360, 2017 Mar.
[Is] ISSN:1546-170X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Opiates are essential for treating pain, but termination of opiate therapy can cause a debilitating withdrawal syndrome in chronic users. To alleviate or avoid the aversive symptoms of withdrawal, many of these individuals continue to use opiates. Withdrawal is therefore a key determinant of opiate use in dependent individuals, yet its underlying mechanisms are poorly understood and effective therapies are lacking. Here, we identify the pannexin-1 (Panx1) channel as a therapeutic target in opiate withdrawal. We show that withdrawal from morphine induces long-term synaptic facilitation in lamina I and II neurons within the rodent spinal dorsal horn, a principal site of action for opiate analgesia. Genetic ablation of Panx1 in microglia abolished the spinal synaptic facilitation and ameliorated the sequelae of morphine withdrawal. Panx1 is unique in its permeability to molecules up to 1 kDa in size and its release of ATP. We show that Panx1 activation drives ATP release from microglia during morphine withdrawal and that degrading endogenous spinal ATP by administering apyrase produces a reduction in withdrawal behaviors. Conversely, we found that pharmacological inhibition of ATP breakdown exacerbates withdrawal. Treatment with a Panx1-blocking peptide ( panx) or the clinically used broad-spectrum Panx1 blockers, mefloquine or probenecid, suppressed ATP release and reduced withdrawal severity. Our results demonstrate that Panx1-mediated ATP release from microglia is required for morphine withdrawal in rodents and that blocking Panx1 alleviates the severity of withdrawal without affecting opiate analgesia.
[Mh] Termos MeSH primário: Comportamento Animal/efeitos dos fármacos
Conexinas/genética
Microglia/efeitos dos fármacos
Morfina/efeitos adversos
Entorpecentes/efeitos adversos
Proteínas do Tecido Nervoso/genética
Células do Corno Posterior/efeitos dos fármacos
Síndrome de Abstinência a Substâncias/genética
[Mh] Termos MeSH secundário: Trifosfato de Adenosina/metabolismo
Animais
Apirase/farmacologia
Western Blotting
Técnicas de Cultura de Células
Técnicas de Cocultura
Conexinas/antagonistas & inibidores
Conexinas/metabolismo
Mefloquina/farmacologia
Camundongos
Microglia/metabolismo
Naloxona/farmacologia
Antagonistas de Entorpecentes/efeitos adversos
Proteínas do Tecido Nervoso/antagonistas & inibidores
Proteínas do Tecido Nervoso/metabolismo
Neurônios/efeitos dos fármacos
Neurônios/metabolismo
Nociceptividade/efeitos dos fármacos
Células do Corno Posterior/metabolismo
Probenecid/farmacologia
Ratos
Síndrome de Abstinência a Substâncias/etiologia
Síndrome de Abstinência a Substâncias/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Connexins); 0 (Narcotic Antagonists); 0 (Narcotics); 0 (Nerve Tissue Proteins); 0 (Panx1 protein, mouse); 0 (pannexin 1, rat); 36B82AMQ7N (Naloxone); 76I7G6D29C (Morphine); 8L70Q75FXE (Adenosine Triphosphate); EC 3.6.1.5 (Apyrase); PO572Z7917 (Probenecid); TML814419R (Mefloquine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170807
[Lr] Data última revisão:
170807
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170131
[St] Status:MEDLINE
[do] DOI:10.1038/nm.4281


  7 / 2003 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28077744
[Au] Autor:Eick-Cost AA; Hu Z; Rohrbeck P; Clark LL
[Ad] Endereço:Epidemiology and Analysis Section, Armed Forces Health Surveillance Branch, Defense Health Agency, Silver Spring, Maryland. angelia.a.cost.ctr@mail.mil.
[Ti] Título:Neuropsychiatric Outcomes After Mefloquine Exposure Among U.S. Military Service Members.
[So] Source:Am J Trop Med Hyg;96(1):159-166, 2017 Jan 11.
[Is] ISSN:1476-1645
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Mefloquine was widely prescribed to U.S. military service members until 2009 when use was limited to personnel with contraindications to doxycycline and no contraindications to mefloquine. The need to estimate the occurrence of neuropsychiatric outcomes (NPOs) in service members prescribed mefloquine warranted a comprehensive evaluation of this issue. Active component service members filling a prescription for mefloquine, doxycycline, or atovaquone/proguanil (A/P) between January 1, 2008 and June 30, 2013, were included in the analysis. The risk of developing incident NPOs and the risk of subsequent NPOs among subjects with a history of the condition were assessed. A total of 367,840 individuals were evaluated (36,538 received mefloquine, 318,421 received doxycycline, and 12,881 received A/P). Among deployed individuals prescribed mefloquine, an increased risk of incident anxiety was seen when compared with doxycycline recipients (incidence rate ratio [IRR] = 1.12 [1.01-1.24]). Among nondeployed mefloquine recipients, an increased risk of posttraumatic stress disorder (PTSD) was seen when compared with A/P recipients (IRR = 1.83 [1.07-3.14]). An increased risk of tinnitus was seen for both deployed and nondeployed mefloquine recipients compared with A/P recipients (IRR = 1.81 [1.18-2.79]), 1.51 (1.13-2.03), respectively). Six percent of the mefloquine cohort had an NPO in the year before receiving mefloquine. When comparing individuals with a prior neuropsychiatric history to those without, the ratio of relative risks for adjustment disorder, anxiety, insomnia, and PTSD were higher (not statistically significant) for mefloquine compared with doxycycline. These findings emphasize the continued need for physicians prescribing mefloquine to conduct contraindication screening.
[Mh] Termos MeSH primário: Doenças do Sistema Nervoso Central/induzido quimicamente
Mefloquina/efeitos adversos
Mefloquina/farmacologia
Militares
[Mh] Termos MeSH secundário: Adolescente
Adulto
Antimaláricos/administração & dosagem
Antimaláricos/efeitos adversos
Antimaláricos/farmacologia
Estudos de Coortes
Doxiciclina/administração & dosagem
Doxiciclina/farmacologia
Feminino
Seres Humanos
Masculino
Mefloquina/administração & dosagem
Estudos Retrospectivos
Estados Unidos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antimalarials); N12000U13O (Doxycycline); TML814419R (Mefloquine)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170531
[Lr] Data última revisão:
170531
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170113
[St] Status:MEDLINE
[do] DOI:10.4269/ajtmh.16-0390


  8 / 2003 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28068604
[Au] Autor:Barbosa-Lima G; Moraes AM; Araújo AD; da Silva ET; de Freitas CS; Vieira YR; Marttorelli A; Neto JC; Bozza PT; de Souza MV; Souza TM
[Ad] Endereço:Instituto Oswaldo Cruz, Fiocruz - Fundação Oswaldo Cruz, Rio de Janeiro, Brazil; Centro de Desenvolvimento Tecnológico em Saúde, Fiocruz - Fundação Oswaldo Cruz, Rio de Janeiro, Brazil; Instituto Nacional de Infectologia Evandro Chagas, Fiocruz - Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
[Ti] Título:2,8-bis(trifluoromethyl)quinoline analogs show improved anti-Zika virus activity, compared to mefloquine.
[So] Source:Eur J Med Chem;127:334-340, 2017 Feb 15.
[Is] ISSN:1768-3254
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:Zika virus (ZIKV), an arthropod-born Flavivirus, has been associated with a wide range of neurological diseases in adults, foetuses and neonates. Since no vaccine is available, repurposing of antiviral drugs currently in medical use is necessary. Mefloquine has confirmed anti-ZIKV activity. We used medicinal chemistry-driven approaches to synthesize and evaluate the ability of a series of new 2,8-bis(trifluoromethyl)quinoline derivatives to inhibit ZIKV replication in vitro, in order to improve the potency of mefloquine. We found that quinoline derivatives 3a and 4 were the most potent compounds within this series, both with mean EC values of 0.8 µM, which represents a potency 5 times that of mefloquine. These results indicate that new 2,8-bis(trifluoromethyl)quinoline chemical structures may be promising for the development of novel anti-ZIKV drugs.
[Mh] Termos MeSH primário: Antivirais/química
Antivirais/farmacologia
Mefloquina/farmacologia
Quinolinas/química
Quinolinas/farmacologia
Zika virus/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Antivirais/síntese química
Antivirais/toxicidade
Cercopithecus aethiops
Desenho de Drogas
Quinolinas/síntese química
Quinolinas/toxicidade
Relação Estrutura-Atividade
Células Vero
Replicação Viral/efeitos dos fármacos
Zika virus/fisiologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiviral Agents); 0 (Quinolines); TML814419R (Mefloquine)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170228
[Lr] Data última revisão:
170228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170110
[St] Status:MEDLINE


  9 / 2003 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28063022
[Au] Autor:Nevin RL; Leoutsakos JM
[Ad] Endereço:Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St., Baltimore, MD, 21205, USA. rnevin@jhu.edu.
[Ti] Título:Identification of a Syndrome Class of Neuropsychiatric Adverse Reactions to Mefloquine from Latent Class Modeling of FDA Adverse Event Reporting System Data.
[So] Source:Drugs R D;17(1):199-210, 2017 Mar.
[Is] ISSN:1179-6901
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Although mefloquine use is known to be associated with a risk of severe neuropsychiatric adverse reactions that are often preceded by prodromal symptoms, specific combinations of neurologic or psychiatric reactions associated with mefloquine use are not well described in the literature. This study sought to identify a distinct neuropsychiatric syndrome class associated with mefloquine use in reports of adverse events. METHODS: Latent class modeling of US Food and Drug Administration Adverse Event Reporting System (FAERS) data was performed using indicators defined by the Medical Dictionary for Regulatory Activities neurologic and psychiatric high-level group terms, in a study dataset of FAERS reports (n = 5332) of reactions to common antimalarial drugs. RESULTS: A distinct neuropsychiatric syndrome class was identified that was strongly and significantly associated with reports of mefloquine use (odds ratio = 3.92, 95% confidence interval 2.91-5.28), defined by a very high probability of symptoms of deliria (82.7%) including confusion and disorientation, and a moderate probability of other severe psychiatric and neurologic symptoms including dementia and amnesia (18.6%) and seizures (18.1%). The syndrome class was also associated with symptoms that are considered prodromal including anxiety, depression, sleep disturbance, and abnormal dreams, and neurological symptoms such as dizziness, vertigo, and paresthesias. CONCLUSIONS: This study confirms in FAERS reports the existence of a severe mefloquine neuropsychiatric syndrome class associated with common symptoms that may be considered prodromal. Clinical identification of the characteristic symptoms of this syndrome class may aid in improving case finding in pharmacovigilance studies of more serious adverse reactions to the drug.
[Mh] Termos MeSH primário: Sistemas de Notificação de Reações Adversas a Medicamentos
Mefloquina/efeitos adversos
Modelos Psicológicos
Doenças Neurodegenerativas/induzido quimicamente
Doenças Neurodegenerativas/psicologia
Neuropsiquiatria
United States Food and Drug Administration
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Feminino
Seres Humanos
Masculino
Mefloquina/administração & dosagem
Mefloquina/uso terapêutico
Meia-Idade
Sintomas Prodrômicos
Síndrome
Estados Unidos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
TML814419R (Mefloquine)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170503
[Lr] Data última revisão:
170503
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170108
[St] Status:MEDLINE
[do] DOI:10.1007/s40268-016-0167-3


  10 / 2003 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28057491
[Au] Autor:Paiz-Candia B; Islas AA; Sánchez-Solano A; Mancilla-Simbro C; Scior T; Millan-PerezPeña L; Salinas-Stefanon EM
[Ad] Endereço:Facultad de Ciencias Químicas, Universidad Autónoma de Puebla, 14 Sur 6301, CU, San Manuel, Puebla, México. Electronic address: bertin.paiz@gmail.com.
[Ti] Título:Mefloquine inhibits voltage dependent Na 1.4 channel by overlapping the local anaesthetic binding site.
[So] Source:Eur J Pharmacol;796:215-223, 2017 Feb 05.
[Is] ISSN:1879-0712
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Mefloquine constitutes a multitarget antimalaric that inhibits cation currents. However, the effect and the binding site of this compound on Na channels is unknown. To address the mechanism of action of mefloquine, we employed two-electrode voltage clamp recordings on Xenopus laevis oocytes, site-directed mutagenesis of the rat Na channel, and a combined in silico approach using Molecular Dynamics and docking protocols. We found that mefloquine: i) inhibited Na 1.4 currents (IC =60µM), ii) significantly delayed fast inactivation but did not affect recovery from inactivation, iii) markedly the shifted steady-state inactivation curve to more hyperpolarized potentials. The presence of the ß1 subunit significantly reduced mefloquine potency, but the drug induced a significant frequency-independent rundown upon repetitive depolarisations. Computational and experimental results indicate that mefloquine overlaps the local anaesthetic binding site by docking at a hydrophobic cavity between domains DIII and DIV that communicates the local anaesthetic binding site with the selectivity filter. This is supported by the fact that mefloquine potency significantly decreased on mutant Na 1.4 channel F1579A and significantly increased on K1237S channels. In silico this compound docked above F1579 forming stable π-π interactions with this residue. We provide structure-activity insights into how cationic amphiphilic compounds may exert inhibitory effects by docking between the local anaesthetic binding site and the selectivity filter of a mammalian Na channel. Our proposed synergistic cycle of experimental and computational studies may be useful for elucidating binding sites of other drugs, thereby saving in vitro and in silico resources.
[Mh] Termos MeSH primário: Anestésicos Locais/metabolismo
Anestésicos Locais/farmacologia
Mefloquina/metabolismo
Mefloquina/farmacologia
Canal de Sódio Disparado por Voltagem NAV1.4/metabolismo
Bloqueadores do Canal de Sódio Disparado por Voltagem/metabolismo
Bloqueadores do Canal de Sódio Disparado por Voltagem/farmacologia
[Mh] Termos MeSH secundário: Animais
Sítios de Ligação
Relação Dose-Resposta a Droga
Fenômenos Eletrofisiológicos/efeitos dos fármacos
Lidocaína/metabolismo
Lidocaína/farmacologia
Simulação de Acoplamento Molecular
Simulação de Dinâmica Molecular
Mutagênese Sítio-Dirigida
Canal de Sódio Disparado por Voltagem NAV1.4/química
Canal de Sódio Disparado por Voltagem NAV1.4/genética
Conformação Proteica
Ratos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anesthetics, Local); 0 (NAV1.4 Voltage-Gated Sodium Channel); 0 (Voltage-Gated Sodium Channel Blockers); 98PI200987 (Lidocaine); TML814419R (Mefloquine)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170428
[Lr] Data última revisão:
170428
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170107
[St] Status:MEDLINE



página 1 de 201 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde